U.S. SECURITIES AND EXCHANGE COMMISSION
                             Washington, D.C. 20549

                                   FORM 10-QSB


(MARK ONE)

[X] QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF
1934 FOR THE QUARTERLY PERIOD ENDED AUGUST 31, 2001

[ ] TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT
OF 1934 FOR THE TRANSITION PERIOD FROM                 TO


COMMISSION FILE NUMBER:


                       L.O.M. MEDICAL INTERNATIONAL, INC.
        (Exact name of small business issuer as specified in its charter)

DELAWARE                                                              98-0178784
(State or other            (Primary Standard Industrial        (I.R.S. Employer
jurisdiction of            Classification Code Number)       Identification No.)
incorporation or
organization)

 #3-1482 Springfield Road, Kelowna, British Columbia, Canada             V1Y 5V3
(Address of principal executive offices)                              (Zip Code)

         (250) 762-7552(Issuer's Telephone Number, including Area Code)


                              Thomas E. Stepp, Jr.
                                 Stepp Law Group
                           1301 Dove Street, Suite 460
                         Newport Beach, California 92660
                             Telephone: 949.660.9700
                             Facsimile: 949.660.9010
            (Name, Address and Telephone Number of Agent for Service)


                APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY
                   PROCEEDINGS DURING THE PRECEDING FIVE YEARS

Check whether the issuer (1) has filed all reports required to be filed by
Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such
shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days. [x ] Yes [ ]
No

                      APPLICABLE ONLY TO CORPORATE ISSUERS

State the number of shares outstanding of each of the issuer's classes of common
equity, as of the latest practical date. As of August 31, 2001, there were
6,152,811 shares of the issuer's $.001 par value common stock issued and
outstanding.



                                       1
<PAGE>





                  Interim Consolidated Financial Statements of

                        L.O.M. MEDICAL INTERNATIONAL INC.

                        (A Development Stage Enterprise)

                   For the three months ended August 31, 2001




                                       2
<PAGE>



L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Interim Consolidated Balance Sheet
($ United States)

August 31, 2001 and May 31, 2001
<TABLE>
<CAPTION>
-------------------------------------------------------------------------------------------------------------------
                                                                               August 31,              May 31,
                                                                                     2001                 2001
                                                                              (Unaudited)
-------------------------------------------------------------------------------------------------------------------
<S>                                                                               <C>                    <C>
Assets

Current assets
     Cash and cash equivalents                                              $     538,411        $     741,152
     Amounts receivable                                                            31,182               48,106
     Prepaid expenses                                                               5,139                1,455
-------------------------------------------------------------------------------------------------------------------
                                                                                  574,732              790,713

Advances and deposits                                                             163,915              161,415

Fixed assets                                                                       38,405               40,809

Patent costs                                                                        7,294                8,336

-------------------------------------------------------------------------------------------------------------------
                                                                            $     784,346        $   1,001,273
-------------------------------------------------------------------------------------------------------------------

Liabilities and Stockholders' Equity

Current liabilities
     Accounts payable and accrued liabilities                               $      99,126        $     112,083

Minority interest                                                                 284,327              301,727

Share subscriptions (note 2(a))                                                   121,658               22,100

Stockholders' equity
     Capital stock
       5,000,000 preferred shares with a par value of $0.001 per
         share authorized, nil issued
       50,000,000 common shares with a par value of $0.001 per share authorized,
         6,159,611 issued, (May 31, 2001 -
         6,152,811 issued)                                                          6,160                6,154
     Additional paid in capital                                                 3,430,528            3,408,434
     Deficit accumulated during the development stage                          (3,190,757)          (2,882,529)
     Accumulated other comprehensive income                                        33,304               33,304
-------------------------------------------------------------------------------------------------------------------
                                                                                  279,235              565,363
Subsequent events (notes 2(a) and 3)
-------------------------------------------------------------------------------------------------------------------
                                                                            $     784,346        $   1,001,273
-------------------------------------------------------------------------------------------------------------------
</TABLE>

      See accompanying notes to interim consolidated financial statements




                                       3
<PAGE>



L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Statements of Loss
$ United States

For the three months ended August 31, 2001 and 2000 and cumulative from
inception (March 17, 1997) to August 31, 2001 (Unaudited)

<TABLE>
<CAPTION>
----------------------------------------------------------------------------------------------------
                                                From inception              Three months ended
                                              (March 17, 1997)
                                            to August 31, 2001            2001             2000
----------------------------------------------------------------------------------------------------
<S>                                                 <C>                  <C>                <C>
Expenses
     General and administration             $    2,206,114      $       85,065    $      108,215
     Research and development                    1,106,736             231,316            85,319
----------------------------------------------------------------------------------------------------
                                                 3,312,850             316,381           193,534

----------------------------------------------------------------------------------------------------
Loss from operations                            (3,312,850)           (316,381)         (193,534)

Other income
     Interest income                               122,093               8,153            13,659

----------------------------------------------------------------------------------------------------
Net loss                                    $   (3,190,757)     $     (308,228)   $     (179,875)
----------------------------------------------------------------------------------------------------


Loss per common share, basic and diluted    $       (0.66)      $       (0.05)    $       (0.03)

Weighted average common shares,
   basic and diluted                             4,811,652           6,152,885         5,909,401
----------------------------------------------------------------------------------------------------
</TABLE>


          See accompanying notes to consolidated financial statements





                                       4
<PAGE>



L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Interim Consolidated Statement of Cash Flows
($ United States)

For the three months ended August 31, 2001 and 2000 and cumulative from
inception (March 17, 1997) to August 31, 2001 (Unaudited)

<TABLE>
<CAPTION>
-------------------------------------------------------------------------------------------------------------------
                                                        From inception                  Three months ended
                                                     (March 17, 1997)
                                                    to August 31, 2001               2001                 2000
-------------------------------------------------------------------------------------------------------------------
<S>                                                            <C>                  <C>                    <C>
Operating activities
   Net loss for the period                             $    (3,190,757)          (308,228)       $    (179,875)

   Items not involving cash
     Amortization                                               71,164              4,610                4,755
     Gain on sale of fixed assets                               (2,659)                 -                    -
     Write down of product rights and patent costs             374,128                  -                    -
     Compensation cost of stock options issued
       for services                                            295,269                  -                    -
     Foreign exchange gain on redeemable preferred
         Shares                                                (17,400)           (17,400)                   -
   Changes in non-cash working capital
     Accounts receivable                                       (31,182)            16,924               13,697
     Prepaid expenses                                           (5,139)            (3,684)               3,395
     Accounts payable and accrued liabilities                   99,126            (12,957)             (10,550)
-------------------------------------------------------------------------------------------------------------------
                                                            (2,407,450)          (320,735)            (168,578)
Financing
     Issuance of capital stock                               2,288,175             22,100              203,516
     Proceeds from subscriptions for shares                    974,902             99,558              134,290
-------------------------------------------------------------------------------------------------------------------
                                                             3,263,077            121,658              337,806
Investing
     Advances and deposits                                    (163,915)            (2,500)             (33,395)
     Proceeds on disposition of fixed assets                     6,189                  -                    -
     Acquisition of fixed assets                              (102,394)            (1,164)              (5,244)
     Acquisition of product rights                             (90,577)                 -                    -
-------------------------------------------------------------------------------------------------------------------
                                                              (350,697)            (3,664)             (38,639)

Effects of change in exchange rates on cash and                 33,481                  -                    -
-------------------------------------------------------------------------------------------------------------------
Increase (decrease) in cash and cash equivalents               538,411           (202,741)             130,589

Cash and cash equivalents, beginning of period                      -             741,152              959,318
-------------------------------------------------------------------------------------------------------------------
Cash and cash equivalents, end of period               $       538,411      $     538,411        $   1,089,907
-------------------------------------------------------------------------------------------------------------------

Supplementary information:
   Interest paid                                       $            -        $          -          $         -
   Income taxes paid                                                -                   -                    -
Non-cash financing and investing activities:
   Issuance of redeemable preferred shares
     for product rights                                       309,677                   -                    -
-------------------------------------------------------------------------------------------------------------------
   Common shares issued for conversion of
     share subscriptions                                      853,244               6,800              185,513
   Compensation cost of stock options
     issued for services                                      295,269                   -                    -
-------------------------------------------------------------------------------------------------------------------
</TABLE>


See accompanying notes to interim consolidated financial statements



                                       5
<PAGE>


L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Statements of Stockholders' Equity and Comprehensive Income
$ United States

For the period from inception on March 17, 1997 to August 31, 2001
<TABLE>
<CAPTION>
----------------------------------------------------------------------------------------------------------------------------
                                              Capital Stock                          Deficit
                                         ----------------------                  Accumulated     Accumulated
                                             Number                Additional     During the           Other            Tota
                                          of Common                   Paid in    Development   Comprehensive    Stockholders
                                             Shares      Amount       Capital          Stage          Income           Equit
----------------------------------------------------------------------------------------------------------------------------
<S>                                           <C>          <C>          <C>            <C>             <C>             <C>
Common shares issued on incorporation             3  $        1   $         -    $         -    $          -    $          1

Comprehensive income (loss):
  Loss                                            -           -             -       (138,272)              -        (138,272
  Foreign currency translation                    -           -             -              -          13,582          13,582
----------------------------------------------------------------------------------------------------------------------------
Comprehensive loss                                                                                                  (124,690
----------------------------------------------------------------------------------------------------------------------------
Balance, May 31, 1997                             3           1             -       (138,272)         13,582        (124,689

Common shares issued to founders
  and others at $0.001                    4,210,090       4,210             -              -               -           4,210

Common shares issued at $1.00
net of share issue costs                    668,154         668       469,887              -               -         470,555

Common shares issued at $1.00 on
  conversion of share subscriptions         605,000         605       604,395              -               -         605,000

Comprehensive income (loss):
  Loss                                            -           -             -       (293,239)              -        (293,239)
  Foreign currency translation                    -           -             -              -          (7,294)         (7,294)
-----------------------------------------------------------------------------------------------------------------------------
Comprehensive loss                                                                                                  (300,533)
-----------------------------------------------------------------------------------------------------------------------------
Balance, May 31, 1998                     5,483,247       5,484     1,074,282       (431,511)          6,288         654,543

Common shares issued on
  November 30, 1998 at $3.25
  net of share issue costs                   36,300          36        96,726              -               -          96,762

Comprehensive income (loss):
  Loss                                           -            -             -       (726,055)              -        (726,055)
  Foreign currency translation                   -            -             -              -          17,038          17,038
-----------------------------------------------------------------------------------------------------------------------------
Comprehensive loss                                                                                                  (709,017)
-----------------------------------------------------------------------------------------------------------------------------
Balance, May 31, 1999                    5,519,547        5,520     1,171,008     (1,157,566)         23,326          42,288

Common shares issued on
  April 17, 2000 at $3.25
  net of share issue costs                 307,610          308       967,335              -               -         967,643

Common shares issued on
  May 10, 2000 at $3.25 on
  conversion of share
  subscriptions                             19,302           19        62,712              -               -          62,731

Comprehensive income (loss):
  Loss                                           -            -             -       (508,835)              -        (508,835)
  Foreign currency translation                   -            -             -              -           9,978           9,978
----------------------------------------------------------------------------------------------------------------------------
Comprehensive loss                                                                                                  (498,857)
----------------------------------------------------------------------------------------------------------------------------

Balance, May 31, 2000                     5,846,459  $    5,847  $  2,201,055  $  (1,666,401)    $    33,304   $     573,805
----------------------------------------------------------------------------------------------------------------------------
</TABLE>




                                       6
<PAGE>




L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Consolidated Statements of Stockholders' Equity and Comprehensive Income
(continued)
$ United States

For the period from inception on March 17, 1997 to August 31, 2001
<TABLE>
<CAPTION>
--------------------------------------------------------------------------------------------------------------------
                                                                           Deficit
                                     Capital Stock                     Accumulated     Accumulated
                                ----------------------
                                    Number                Additional    During the           Other          Total
                                 of Common                   Paid in   Development   Comprehensive  Stockholders'
                                    Shares      Amount       Capital         Stage          Income         Equity
--------------------------------------------------------------------------------------------------------------------
<S>                                  <C>         <C>           <C>            <C>            <C>            <C>
Balance, May 31, 2000,
  carried forward                5,846,459  $    5,847  $   2,201,055  $ (1,666,401)    $     33,304  $     573,805

Common shares issued on
  September 22, 2000 for
  cash at $3.25 net of share
  issue costs                      249,271         250        726,654             -                -        726,904

Common shares issued on
  December 19, 2000 at $3.25
  on conversion of share
  subscriptions                     57,081          57        185,456             -                -        185,513

Compensation costs for
  stock options issued for
  services (note 5(b))                   -           -        295,269             -                -        295,269

Comprehensive income (loss):
  Loss                                   -           -              -    (1,216,128)               -     (1,216,128)
  Foreign currency translation           -           -              -             -                -              -
--------------------------------------------------------------------------------------------------------------------
Comprehensive loss                                                                                       (1,216,128)
--------------------------------------------------------------------------------------------------------------------
Balance, May 31, 2001            6,152,811  $    6,154  $   3,408,434  $ (2,882,529)    $     33,304  $     565,363

Common shares issued on
  August 31, 2001 at $3.25
  on conversion of share
  subscriptions                      6,800           6         22,094             -                -         22,100

Comprehensive income (loss):
  Loss                                   -           -              -      (308,228)               -       (308,228)
  Foreign currency translation           -           -              -             -                -              -
--------------------------------------------------------------------------------------------------------------------
Comprehensive loss                                                                                         (308,228)
--------------------------------------------------------------------------------------------------------------------
Balance, August 31, 2001         6,159,611  $    6,160  $   3,430,528  $ (3,190,757)    $     33,304  $     279,235
--------------------------------------------------------------------------------------------------------------------
</TABLE>



                                       7
<PAGE>



L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Notes to Consolidated Financial Statements
($ United States)

(Unaudited)

-------------------------------------------------------------------------------

L.O.M. Medical International Inc. was incorporated on March 17, 1997 under the
General Corporation Laws of Delaware. It conducts research and development on
new products in the medical field including a retractable syringe. Operations
effectively commenced on June 1, 1997. These interim consolidated financial
statements should be read in conjunction with the annual financial statements
for the year ended May 31, 2001 filed under cover of Form 10-KSB.

1.   Significant accounting policies:

     a)  Going concern

         These financial statements have been prepared by management on the
         going concern basis in accordance with generally accepted accounting
         principles in the United States of America, which assumes the
         realization of assets and liquidation of liabilities and commitments in
         the normal course of business. As shown in the consolidated financial
         statements, to date, the Company has generated no revenues and has
         accumulated a deficit since inception of $3,190,757. These factors,
         among others, raise substantial doubt about the Company's ability to
         continue as a going concern. The Company's ability to continue as a
         going concern is dependent on its ability to generate future profitable
         operations and receive continued financial support from its
         stockholders and other investors.

         Management's plans with respect to generating future profitable
         operations include future sales of the retractable syringe as well as
         additional funding from stockholders in the form of additional share
         subscriptions. There can be no assurance that a market will develop for
         the retractable syringe or that additional share financings will be
         available. Failure to obtain adequate financing will cause the Company
         to curtail operations.

     b)  Management estimates

         The preparation of financial statements in conformity with generally
         accepted accounting principles in the United States of America requires
         management to make estimates and assumptions that affect the reported
         amounts of assets and liabilities and disclosures of contingent assets
         and liabilities at the date of the financial statements and the
         reported amounts of revenues and expenses during the reporting period.
         Actual results could differ from those estimates.

2.   Capital stock:

     a)  Share subscriptions:

         Subsequent to August 31, 2001, the Company issued 41,711 common shares
         at $3.25 per share for net proceeds of $121,658 after share issuance
         costs of $13,903.




                                       8
<PAGE>



L.O.M. MEDICAL INTERNATIONAL INC.
(A Development Stage Enterprise)

Notes to Consolidated Financial Statements
($ United States)

(Unaudited)

-------------------------------------------------------------------------------

2.   Capital stock (continued):

     b)  Stock options

         The Company has 340,417 options outstanding with a weighted average
         exercise price of $3.25. The remaining contractual life of the
         outstanding options is 7.5 years. No options were issued, exercised,
         expired or cancelled during the three months ended August 31, 2001.

     c)  Warrants:

         3,076,405 warrants were issued during fiscal 2001 to existing
         shareholders representing 1/2 warrant for each common share held. Each
         warrant entitles the holder of such warrant to purchase one common
         share for $5.00 per share. Each warrant expires ninety days after the
         first transaction in the Company's shares occurs on the
         Over-the-Counter Bulletin Board.

3.    Contingent liability:

      The Company has been engaged in discussions with staff of the British
      Columbia Securities Commission (the "BCSC") concerning the distribution of
      the Company's common stock to certain residents of British Columbia. Staff
      of the BCSC has taken the position that the distribution of certain shares
      may not have, in all circumstances, satisfied the prospectus exemption
      requirements under the Securities Act (British Columbia). In order to
      resolve the concerns of staff of the BCSC, the Company has agreed to make
      an offer of rescission (the "Rescission Offer") to purchasers of its
      common stock residing in British Columbia. The Company mailed the
      Rescission Offer in early August 2001 and such Rescission Offer will be
      open for acceptance for a period of 30 days. Under the Rescission Offer,
      the recipient may elect to retain their shares in the Company or to
      rescind their original purchase and return the shares to the Company and
      receive from the Company, the purchase price originally paid for the
      shares. Any shares returned to the Company pursuant to the Rescission
      Offer will be cancelled. As at August 31, 2001, no stockholders had
      exercised their right to rescission. Subsequent to August 31, 2001,
      stockholders who have acquired 103,676 common stock from the Company for
      aggregate proceeds of approximately $249,924, have exercised their right
      of rescission.




                                       9
<PAGE>




Item 2.  Management's Discussion and Analysis or Plan of Operation

Development of the Company

L.O.M. Medical International Inc., a Delaware corporation ("Company" and "L.O.M.
Medical"), was incorporated in the State of Delaware on March 17, 1997. Our
executive offices are located at #3-1482 Springfield Road, Kelowna, B.C., Canada
V1Y 5V3. Our telephone number is 250.762.7552.

For purposes of clarification, anytime the symbol "US" is used within this
Quarterly Report of Form 10-QSB, it refers to the currency of the United States.
Anytime the symbol "CDN" is used, it refers to the currency of Canada.

Our Business

We were incorporated for the purpose of researching and developing health care
products. The goal is to become an innovator and provider of a retractable
syringe ("Syringe") and related products and technologies to the health care
market. We have successfully patented and licensed products in seventy countries
including the United States and Canada and continue to maintain these patents.
We plan to develop new and improved products and provide the health care
industry with better, safer products throughout the world.

The Retractable Syringe

We believe the Syringe will change standard disposal methods for used syringes.
We have developed a product designed to function, as a standard hypodermic
syringe that we believe is safer to the caregiver or health care worker. We
believe that the Syringe's unique design will allow health care providers to
avoid direct contact with used needles. The Syringe is covered by United States
Patent No. 5,868,713 dated February 9, 1999, and international patents have been
filed in 84 different countries.

Once the needle is injected, the user simply has to press the plunger top gently
with his or her thumb to automatically retract the needle into its own sealed
chamber. The needle is now hidden where it remains locked in place and cannot be
used again. The Syringe does not require a health care worker to use both hands
to retract the needle after it has been used and withdrawn from the patient. The
Syringe will be produced in standard industry sizes from 1CC to 20CC, inclusive.

We intend to promote the Syringe as a safer and less risk-oriented instrument
for hospital staff and health care workers. We are optimistic that doctors,
nurses, and health care workers alike will recognize and appreciate the safety
features of the Syringe because of its ease of "use-and-disposal" and its unique
"contaminate-prevention" characteristics. However, we currently have no
contracts to sell the Syringe and there are no guarantees as to the timing of
any such contracts in the future.

It is anticipated that the products and technologies developed by us will be
offered to distributors on a worldwide basis, with an initial emphasis in Canada
and the United States. It is hoped that new product and technology ideas will be
generated through active dialogues among our potential customers, and our
network of scientific advisors. We also hope to participate in national and
international conferences, and to generate reviews in selected scientific
literature.

Management interacts with a network of scientific advisors within the industry,
including members of academic institutions, as well as potential customers. We
anticipate that these interactions will enable us to identify the specialized
needs of those potential customers and to provide innovative and commercially
acceptable products and technologies. At this time, our relationship with
scientific advisors and academic institutions is limited to an advisory
relationship. We anticipate testing the Syringe in conjunction with teaching
universities in Canada, Britain, and other constituents of the United Kingdom.

We have manufactured a Proof Of Concept Prototype ("POCP") Syringe. A POCP is a
device designed to show that the patented idea or invention can be made into a
viable product. We are now at the next step, which is to make 5,000 prototypes
that are virtually the same as the finished product. We have contacted the FDA
and they have indicated that we will not have to have a pre market approval
(PMA) for the Syringe before we move to the next phase.




                                       10
<PAGE>



Last year, a propellant was selected from a large pool of possibilities to power
the cell for the Syringe. The propellant had to meet many criteria. We have
found a material that, according to our preliminary research, meets the desired
criteria and has been encapsulated in a polymer to form a cell. We have not yet
completed our research, however, and unanticipated problems may arise. This cell
has proved to generate more than enough power to retract a needle. We hope to
produce a cell with a 2-year shelf life. Currently we have developed a cell with
a 3-6 month shelf.

We have obtained information on syringe design and practicality from
interviewing nursing practitioners. We also determined the thumb-force required
to activate retraction of the needle. We have incorporated the results of our
analysis into our POCP.

We believe that the POCP has shown benefits over spring-powered syringes. With
design modifications, we hope to tailor the speed of retraction while
maintaining the smooth retraction of the needle. We hope this will eliminate the
type of blood splattering sometimes experienced with spring-loaded syringes.

We continue to finalize our work with B.C. Tech Inc. Currently we are having
molds prepared that will produce the first 5,000 prototype units of the Syringe.
We expect to receive the prototypes in the second quarter of 2001. The
development of the prototypes was achieved within our budgeted $400,000. To date
we have expensed approximately $390,000 for this work. We have started
interviewing various companies that we hope will be able to construct the next
level of molds for 100,000 units of our Syringe.

We plan to meet our financial obligation under these agreements over the next
several months from existing cash resources and additional capital financing.
From our inception on March 17, 1997, to August 31, 2001 we have incurred
$1,106,736 in development costs related to the Syringe, including the proof of
concept prototype, molds for test Syringes, and eye care products.

Over the next 12 months, we plan to focus our efforts in the following areas:

     o    The manufacture of 5,000 prototype Syringes;

     o    Perform design refinements on the Syringe in an effort to minimize
          parts and make manufacturing as simple and cost-effective as possible;

     o    Contact the Food and Drug Administration ("FDA") in anticipation of a
          510K submission;

     o    Sterilization selection (E beam and Y beam);

     o    Material compatibility; and

     o    Mould maker selection.

During the next 12 months we anticipate increases in our staffing and
contracting out levels as the prototype of the Syringe hopefully moves forward.
Dr. Simon Wood has agreed to run the research and development department.
Currently, he invoices us on an hourly basis for work completed. There is no
written contract in place with him at this time. We have also subcontracted with
Kevin Conway, a mid-level engineer for services. Mr. Conway performs subcontract
work on an hourly basis. He is assisting with CAD-CAM requirements relating to
the development of the Syringe.

We are not currently producing commercial quantities of products or currently
supplying any services to any third parties. No assurance can be given that we
will, on a timely basis, be able to make the transition from manufacturing
testing quantities of the Syringe to commercial production quantities
successfully or be able to arrange for contract manufacturing.

We anticipate contracting out the first two years of commercial production of
the Syringe. At the end of the second year of production, we anticipate engaging
in significant discussions regarding the potential for the construction of our
own production facility. We recognize that the construction of a production
facility will be contingent upon us having reached our sales and profit
projections. We anticipate this issue will be presented for vote by our Board of
Directors and shareholders. Negotiations to set up a manufacturing plant in
Ireland have begun but have not progressed beyond the preliminary discussions
discussed in our previous filings.




                                       11
<PAGE>




The Eye Care System

We have invented and developed an insertion and storage device for contact
lenses (the "Eye Care System"), which is a method of handling and inserting
contact lenses. We have developed the following components and solutions that
will be used together with the Eye Care System insertion and storage products:

     o    a medical inserter that will remove contact lenses in a medical
          emergency situation for use by hospital medical staff and paramedics;
     o    disposable and replacement inserter ends;
     o    additional storage cups and caps; and
     o    all soaking and disinfecting solutions that are to be used with the
          Eye Care System inserter.

The Eye Care System is designed so that the practitioner will no longer have
direct hand or finger contact with the contact lens when fitting the patient. We
believe that the design of the system will reduce the risk of contamination and
infection to the patient. We have developed a liquid cleaner for the Eye Care
System that quickly cleans contact lenses. We have obtained Food and Drug
Administration Approval ("FDA") for the Eye Care System product.

We have completed market testing and believe that the Eye Care System was well
received at the American Optometrists Association convention in Montreal,
Canada, where approximately 30,000 units were distributed to opticians,
optometrists and pharmacies for trial at no charge. We have completed the
formulation of contact lens solutions and copyrights covering these products
have been registered. We have completed the design and labeling of the Eye Care
System. We believe that the eye-care products are ready for marketing and
distribution.

The target markets for the distribution for the Eye Care System product include,
but are not necessarily limited to:

     o    hospitals and clinics, including optometrists and opticians.

The eye care products are currently produced in Canada. We own all of the
necessary injection molds. We will contract out for the production of components
needed for the assembly and packaging of the eye care products. The actual
assembly and packaging will be subcontracted out at this time.

We have produced 33,000 units of our eye care inserters, which will be used for
demonstrations. Currently we have approximately 30,000 units available. As such
we have not inventoried the units but expensed them in the past financial
statements as net realizable value is anticipated to be nil. We currently have
the ability to subcontract out for the production of commercial quantities of
our eye care products. We currently have dies with an output capacity of 150,000
units. There is a second set of dies designed that will have a 300,000 unit
capacity which would allow the production of a total of 450,000 units of eye
care products per month.

We have FDA approval to market our line of eye care products in the United
States and have the necessary Canadian approval to market eye-care products in
Canada. We are reviewing various contracts with third parties to market the Eye
Care System in Canada as well as the United States.

We continue to focus our activities on the production and launch of the Syringe.
When that is finalized, we will implement our marketing plan for the Eye Care
System products.

Skin Care Products

At this time we are reorganizing our approach to the skin care line. We will not
be pursuing this area aggressively until we have our Syringe production under
way.

Genetic Patents




                                       12
<PAGE>




We are currently negotiating licensing agreements with the owners of various
patents on genetic vectors. As of August 31, 2001 we had advanced $46,520 to
date to pay for patents, which has been included in our financial statements as
advances and deposits.

Business of the Our Subsidiary

There has been no activity in our subsidiary this quarter. For the foreseeable
future, our subsidiary will be inactive.

Liquidity and Future Capital Requirements

We had cash resources of $538,411 at August 31, 2001, compared to $741,152 at
May 31, 2001. At August 31, 2001, total current assets exceeded total current
liabilities by $475,606, compared to $678,630 at May 31, 2001. Because we are
not generating any significant revenue, our only external source of liquidity is
the sale of our capital stock. We have no contractual obligations for capital
purchase or any other commitments except for the obligation to refund to certain
stockholders resident in British Columbia the original purchase price paid for
common stock in the amount of $249,924 (see Item 1 entitled "Legal Proceedings"
below). The obligation arose subsequent to August 31, 2001 pursuant to
shareholders exercising their rights of rescission. Accordingly, at our current
rate of expenditure and existing cash resources, we forecast that our cash
resources will be sufficient to allow us to meet our financial obligations until
November 15, 2001. Accordingly, we will require additional cash to implement our
business strategy of developing, promoting, producing and distributing our
proposed products. Such additional capital may be raised through additional
public or private financings, as well as borrowings and other resources. No
assurance can be given, however, that we will have access to the capital markets
in the future, or that financing will be available on acceptable terms to
satisfy our cash requirements necessary to implement our business strategy. The
inability to access the capital markets or obtain acceptable financing could
have a material adverse effect on our results of operations and financial
condition. If we do not raise additional cash during this period, we will have
to severely restrict our operations until we have sufficient cash to move
forward. To the extent that additional capital is raised through the sale of
equity or equity-related securities, the issuance of such securities could
result in dilution of the stockholders.

Our forecast of the period of time through which the financial resources will be
adequate to support the operations is a forward-looking statement that involves
risks and uncertainties, and actual results could vary as a result of a number
of factors.

Business Risks

Because of the nature of our business, we will be exposed to a variety of
business risks, some of which are inherent to all competitive commercial
enterprises and others that are specific to the medical products industry. We
will endeavor to limit all specific risk factors through our disciplined
management of operation and financial strategies.

Financial Risks

Our business plans of are aggressive in nature. Continued rapid business
expansion will consume valuable working capital and result in significant demand
on cash flow from operations over the next few quarters. We expect that existing
capital resources and contributions from profits will not be sufficient to fund
our business plans as represented without assembling additional funds from
external sources.

Business Cycles and Risks of Cost Overruns

The sale and implementation of our products involves a reasonable market
penetration. Failure to secure reasonable market penetration could have adverse
effects on our business, results of operations and our financial condition.

Fluctuations in Financial Results

Our operating results will fluctuate, depending on factors such as the demand
for products, the size and timing of contracts, new products and enhancements,
price competition, changes in operating expenses and personnel and general
economic factors. Therefore, actual financial results may vary significantly
from those projected by management.




                                       13
<PAGE>




Third-Party Claims for Infringement

We are not aware that any of our products infringe on the proprietary rights of
third parties. There can be no assurance, however, that third parties will not
claim such infringements by us with respect to current or future products. Any
such claims, with or without merit, could be time consuming, result in costly
litigation, or cause product or shipment delays. Any of the foregoing could have
adverse effects on our business, results of operations or financial condition.

Dependence of Single Product Line

Concentration of sales in a single product line for the medical health industry
represents a substantial risk should market conditions deteriorate.

Foreign Currency

Our business plans are primarily focused on the penetration in the United States
and subsequently worldwide markets, therefore, we will be subject to the risk of
foreign currency fluctuations.

Competition and Sales Channels

Several companies compete with us in the syringe market; however, we believe and
there are a few competitors in the safety syringe market. Those that do exist
are substantially larger and possess greater financial resources than us. Our
future success, however, relies on achieving superior product development
through greater focus on the needs of the market and faster response to evolving
customer requirements. There can be no assurance, however, that competitors will
not develop products superior to our products or achieve greater market
acceptance due to marketing, sales channels or other factors.

Dependence on Large Distributors

We will rely in part on business partners for the distribution of our products.
This includes a few large distributors in the United States. We may be impacted
by negative business cycles or events experienced by these distributors. This
may lead to a short or long term reduction in revenue.

Human Resource Risks and Growth

Our success is largely dependent on the performance of our key employees.
Failure to attract and retain key employees with necessary skills could have an
adverse impact upon our growth and profitability. We hope to expand our business
in the near future. This expansion could result in substantial growth in the
number of employees, the scope of our operating and financial systems and the
geographic area of our operations. This increases the responsibilities for both
existing and new management personnel. Our ability to support the projected
growth of our business will be dependent upon having highly trained personnel in
place to conduct pre-sales activities, product implementation and other customer
support services. Future operating results will depend on the ability of our key
managers and employees to continue to implement and improve its operational,
customer support and financial systems. There can be no assurance that we will
be able to manage any future expansion successfully, and if we cannot, this
could adversely affect our results of operations and financial health.

Production and Quality Control

The manufacturing of products involves a number of steps and requires compliance
with stringent quality control specifications imposed on us by various
regulators. We may not be able to quickly replace manufacturing capacity if we
were unable to use our manufacturing facilities as a result of a fire, natural
disaster (including earthquake), equipment failure or other difficulty, or if
such facilities are deemed not in compliance with the various regulators'
requirements and the non-compliance could not be rapidly rectified. The
inability or reduced capacity to manufacture or have manufactured any of our
products would have a material adverse effect on the business and results of
operations.




                                       14
<PAGE>




Government Standards and Regulations

Our products will be subject to numerous foreign government standards and
regulations that are continually being amended. Although we will endeavor to
satisfy foreign technical and regulatory standards, there can be no assurance
that the products will comply with foreign government standards and regulations,
or changes thereto, or that it will be cost effective to redesign the products
to comply with such standards or regulations. The inability to design or
redesign products to comply with foreign standards could have a material adverse
effect on our business, financial condition and results of operations.

Product Liability Risk

Our business will expose us to potential product liability risks that are
inherent in the testing, manufacturing and marketing of medical products. We do
not currently have product liability insurance, and there can be no assurance
that we will be able to obtain or maintain such insurance on acceptable terms
or, if obtained, that such insurance will provide adequate coverage against
potential liabilities.

We face an inherent business risk of exposure to product liability and other
claims in the event that the development or use of our technology or products is
alleged to have resulted in adverse effects. Such risk exists even with respect
to those products that are manufactured in licensed and regulated facilities or
that otherwise possess regulatory approval for commercial sale. There can be no
assurance that we will avoid significant product liability exposure. There can
be no assurance that insurance coverage will be available in the future on
commercially reasonable terms, or at all, or that such insurance will be
adequate to cover potential product liability claims or that a loss of insurance
coverage or the assertion of a product liability claim or claims would not
materially adversely affect our business, financial condition and results of
operations.

While we have taken, and will continue to take, what we believe are appropriate
precautions, there can be no assurance that we will avoid significant liability
exposure. An inability to obtain product liability insurance at acceptable cost
or to otherwise protect against potential product liability claims could prevent
or inhibit the commercialization of the products. A product liability claim
could have a material adverse effect on the business, financial condition and
results of operations.

Results of Operations

We have not yet realized any revenues from operations. The net loss from March
17, 1997 (inception) to August 31, 2001, was $3,190,757. The net loss for the
3-month period ended August 31, 2001, was $308,228 compared to a loss of
$179,875 for the 3-month period ended August 31, 2000. The net loss for the
12-month period ended May 31, 2001, was $1,216,128. Such losses were primarily
the result of product development and operational expenditures.

In the 3 month period ended August 31, 2001, our losses increased compared to
the prior comparable period because we are now funding the development of the
Syringe. During the 3-month period ended August 31, 2001 we paid out $231,316
for development of the Syringe, including a prototype. During the same period in
2001, we expended $9,753 for the same development expenses. Included in general
and administration expenses is $20,643 in legal and accounting fees for the
3-month period ending August 31, 2001, compared to $50,400 for the 3-month
period ending August 31, 2000. Consulting fees for the 3-month period ending
August 31, 2001 were $33,912.

During the 3-month period ended August 31, 2001, the following material changes
in our financial conditions occurred:

     o    Advances and deposits increased from $161,415 at May 31, 2001 to
          $163,415 at August 31, 2001. This increase is due to $2,500 additional
          funds advanced to the owners of various patents on genetic vectors.

     o    Capital stock and additional paid in capital have increased by $6,800
          and $422,093 since May 31, 2001.

Item 1. Legal Proceedings

Litigation Involving Our Subsidiary.




                                       15
<PAGE>



At the present time our subsidiary has been named in small claims court as a
defendant regarding a suit over certain architectural drawings. The claim
relates to allegedly excessive charges of approximately $5,000CDN that was
invoiced to our subsidiary without approval. We have attempted to settle this
with the claimant several times with little success. The matter has been brought
before the small claims court. A claim in small claims court cannot exceed
$10,000CDN. We hope to settle the claim for less than the invoiced amount.

British Columbia Securities Commission.

We have been engaged in discussions with staff of the British Columbia
Securities Commission ("BCSC") concerning the distribution of the Company's
common stock to certain residents of British Columbia. Staff of the BCSC has
taken the position that the distribution of certain shares may not have, in all
circumstances, satisfied the prospectus exemption requirements under the
Securities Act of British Columbia. In order to resolve the concerns of staff of
the BCSC, we have agreed to make an offer of rescission (the "Rescission Offer")
to purchasers of the Company's common stock residing in British Columbia. The
Rescission Offer was mailed to the British Columbia shareholders on August 10,
2001. Such Rescission Offer remained open for acceptance until September 10,
2001. Under the Rescission Offer, the recipient could elect to retain their
shares in the Company or to rescind their original purchase and return the
shares to the Company and receive from the Company, the purchase price
originally paid for the shares. Any shares returned to the Company pursuant to
the Rescission Offer will be cancelled. As at August 31, 2001 no stockholders
had exercised their right of rescission. As of September 10, 2001 stockholders
holding 103,676 common stock with a paid up capital of $ 249,924, have exercised
their right of rescission.

Item 2. Changes in Securities

Warrants. We have offered to all shareholders of record as at June 30 2001, one
warrant for every two shares held by each shareholder. Each warrant entitles the
holder of such warrant to purchase one share of our common stock for $5.00 per
share. Each warrant expires by its own terms ninety days after the first
transaction in the Company's shares occurs on a public market.

Stock Options. Our Board of Directors has adopted a stock option plan ("Stock
Option Plan"). The Stock Option Plan is designed to retain qualified and
competent officers, employees and directors. Our Board of Directors, or a
committee thereof, shall administer the Stock Option Plan and is authorized, in
its sole and absolute discretion, to grant options to all our eligible
employees, including our officers and directors (whether or not employees).
Options granted pursuant to the Stock Option Plan will be exercisable within the
period specified in the stock option agreement. Options granted under the Stock
Option Plan will not be exercisable after the expiration of ten (10) years from
the date of grant for shareholders with less than 10% ownership and five (5)
years for shareholders with 10% or more share ownership. The Stock Option Plan
will also authorize us to make loans to optionees to enable them to exercise
their options. As of August 31, 2001, we had 340,417 options outstanding with a
weighted average exercise price of $3.25. The remaining contractual life of the
outstanding options is 7.5 years. No options were issued, exercised, expired or
cancelled during the three months ended August 31, 2001.

Item 3.  Defaults Upon Senior Securities

None

Item 4.  Submission of Matters to Vote of Security Holders

None

Item 5.  Form 3

None

Item 6.  Exhibits and Reports on Form 8-K

None



                                       16
<PAGE>




SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.

Dated:   October 1, 2001             L.O.M. Medical International, Inc.


                                     By:      /s/ John Klippenstein
                                              -------------------------------
                                              John Klippenstein
                                     Its:     President